The U.S. Food and Drug Administration, FDA, on Tuesday approved the so-called "little pink pill" marketed as Addyi to treat acquired, generalized hypoactive sexual desire disorder (HSDD). In simpler words, the controversial drug is intended to boost decreasing sex drive in women.
